Guralnik, JM, Eisenstaedt, RS, Ferrucci, L. Prevalence of anemia in persons 65 years and older in the United States: evidence for a high rate of unexplained anemia. Blood. 2004;104(8):2263–2268.CrossRefGoogle ScholarPubMed

Salive, ME, Cornoni-Huntley, J, Guralnik, JM. Anemia and hemoglobin levels in older persons: relationship with age, gender, and health status. J Am Geriatr Soc. 1992;40(5):489–496.CrossRefGoogle ScholarPubMed

Ania, BJ, Suman, VJ, Fairbanks, VF. Prevalence of anemia in medical practice: community versus referral patients. Mayo Clin Proc. 1994;69(8):730–735.CrossRefGoogle ScholarPubMed

Joosten, E, Pelemans, W, Hiele, M. Prevalence and causes of anaemia in a geriatric hospitalized population. Gerontology. 1992;38(1–2):111–117.CrossRefGoogle Scholar

Ania, BJ, Suman, VJ, Fairbanks, VF. Incidence of anemia in older people: an epidemiologic study in a well defined population. J Am Geriatr Soc. 1997;45(7):825–831.CrossRefGoogle Scholar

Nilsson-Ehle, H, Jagenburg, R, Landahl, S. Haematological abnormalities and reference intervals in the elderly: a cross-sectional comparative study of three urban Swedish population samples aged 70, 75 and 81 years. Acta Med Scand. 1988;224(6):595–604.CrossRefGoogle ScholarPubMed

Artz, AS, Fergusson, D, Drinka, PJ. Mechanisms of unexplained anemia in the nursing home. J Am Geriatr Soc. 2004;52(3):423–427.CrossRefGoogle ScholarPubMed

Coiffier, B, Guastalla, JP, Pujade-Lauraine, E. Anemia Study Group. Predicting cancer-associated anaemia in patients receiving non-platinum chemotherapy: results of a retrospective survey. Eur J Cancer. 2001;37(13):1617–1623.CrossRefGoogle Scholar

Kyle, RA. Multiple myeloma: review of 869 cases. Mayo Clin Proc. 1975;50(1):29–40.Google ScholarPubMed

Bokemeyer, C, Oechsle, K, Hartmann, JT. Anaemia in cancer patients: pathophysiology, incidence and treatment. Eur J Clin Invest. 2005;35(suppl 3):26–31.CrossRefGoogle ScholarPubMed

Dainiak, N, Kulkarni, V, Howard, D. Mechanisms of abnormal erythropoiesis in malignancy. Cancer. 1983;51(6):1101–1106.3.0.CO;2-G>CrossRefGoogle ScholarPubMed

Hamblin, TJ, Orchard, JA, Myint, H. Fludarabine and hemolytic anemia in chronic lymphocytic leukemia. J Clin Oncol. 1998;16(9):3209–3210.CrossRefGoogle ScholarPubMed

Rytting, M, Worth, L, Jaffe, N. Hemolytic disorders associated with cancer. Hematol Oncol Clin North Am. 1996;10(2):365–376.CrossRefGoogle ScholarPubMed

Ludwig, H, Fritz, E. Anemia in cancer patients. Semin Oncol. 1998;25(3 suppl 7):2–6.Google ScholarPubMed

Skillings, JR, Sridhar, FG, Wong, C. The frequency of red cell transfusion for anemia in patients receiving chemotherapy: a retrospective cohort study. Am J Clin Oncol. 1993;16(1):22–25.CrossRefGoogle ScholarPubMed

Pirker, R, Krajnik, G, Zochbauer, S. Paclitaxel/cisplatin in advanced non-small-cell lung cancer (NSCLC). Ann Oncol. 1995;6(8):833–835.CrossRefGoogle Scholar

Dalton, JD, Bailey, NP, Barrett-Lee, PJ. Multicenter UK audit of anemia in patients receiving cytotoxic. Proc Am Soc Clin Oncol. 1998;17:418a.Google Scholar

Hensley, ML, Lebeau, D, Leon, LF. Identification of risk factors for requiring transfusion during front-line chemotherapy for ovarian cancer. Gynecol Oncol. 2001;81(3):485–489.CrossRefGoogle ScholarPubMed

Pivot, X, Guardiola, E, Etienne, M. An analysis of potential factors allowing an individual prediction of cisplatin-induced anaemia. Eur J Cancer. 2000;36(7):852–857.CrossRefGoogle ScholarPubMed

Wiltshaw, E, Kroner, T. Phase II study of cis-dichlorodiammineplatinum(II) (NSC-119875) in advanced adenocarcinoma of the ovary. Cancer Treat Rep. 1976;60(1):55–60.Google ScholarPubMed

Rossof, AH, Slayton, RE, Perlia, CP. Preliminary clinical experience with cis-diamminedichloro-platinum (II) (NSC 119875, CACP). Cancer. 1972;30(6):1451–1456.3.0.CO;2-Q>CrossRefGoogle Scholar

Wood, PA, Hrushesky, WJ. Cisplatin-associated anemia: an erythropoietin deficiency syndrome. J Clin Invest. 1995;95(4):1650–1659.CrossRefGoogle ScholarPubMed

Ahn, SH, Garewal, HS. Low erythropoietin level can cause anemia in patients without advanced renal failure. Am J Med. 2004;116(4):280–281.CrossRefGoogle ScholarPubMed

Coskun, HS, Yilmaz, O, Alanoglu, G. Chemotherapy-associated anemia in solid tumors patients from Anatolia. Proc Am Soc Clin Oncol. 2005;23(16S):8257.Google Scholar

Barrett-Lee, PJ, Ludwig, H, Birgegard, G. Independent risk factors for anemia in cancer patients receiving chemotherapy: results from the European Cancer Anaemia Survey. Oncology. 2006;70(1):34–48.CrossRefGoogle ScholarPubMed

Vincent, M, Dranitsaris, G, Clemons, M. The development of a prediction tool for chemotherapy-induced anemia in patients with advanced non-small cell lung cancer (NSCLC) palliative receiving chemotherapy [abstract]. J Clin Oncol Meet Abstr. 2006;24(18 suppl):8600.Google Scholar

Du, XL, Osborne, C, Goodwin, JS. Population-based assessment of hospitalizations for toxicity from chemotherapy in older women with breast cancer. J Clin Oncol. 2002;20(24):4636–4642.CrossRefGoogle ScholarPubMed

Kario, K, Matsuo, T, Nakao, K. Serum erythropoietin levels in the elderly. Gerontology. 1991;37(6):345–348.CrossRefGoogle ScholarPubMed

Joosten, E, Hove, L, Lesaffre, E. Serum erythropoietin levels in elderly inpatients with anemia of chronic disorders and iron deficiency anemia. J Am Geriatr Soc. 1993;41(12):1301–1304.CrossRefGoogle ScholarPubMed

Matsuo, T, Kario, K, Kodoma, K. An inappropriate erythropoietic response to iron deficiency anaemia in the elderly. Clin Lab Haematol. 1995;17(4):317–321.Google ScholarPubMed

Ershler, WB, Sheng, S, McKelvey, J. Serum erythropoietin and aging: a longitudinal analysis. J Am Geriatr Soc. 2005;53(8):1360–1365.CrossRefGoogle ScholarPubMed

Lipschitz, DA, Udupa, KB, Milton, KY. Effect of age on hematopoiesis in man. Blood. 1984;63(3):502–509.Google ScholarPubMed

Rothstein, G. Disordered hematopoiesis and myelodysplasia in the elderly. J Am Geriatr Soc. 2003;51(3 suppl):S22–S26.CrossRefGoogle ScholarPubMed

Boggs, DR, Patrene, KD. Hematopoiesis and aging III: anemia and a blunted erythropoietic response to hemorrhage in aged mice. Am J Hematol. 1985;19(4):327–338.CrossRefGoogle Scholar

Rothstein, G, Christensen, RD, Nielsen, BR. Kinetic evaluation of the pool sizes and proliferative response of neutrophils in bacterially challenged aging mice. Blood. 1987;70(6):1836–1841.Google ScholarPubMed

Baraldi-Junkins, CA, Beck, AC, Rothstein, G. Hematopoiesis and cytokines: relevance to cancer and aging. Hematol Oncol Clin North Am. 2000;14(1):45–61.CrossRefGoogle ScholarPubMed

Buchanan, JP, Peters, CA, Rasmussen, CJ. Impaired expression of hematopoietic growth factors: a candidate mechanism for the hematopoietic defect of aging. Exp Gerontol. 1996;31(1–2):135–144.CrossRefGoogle Scholar

Aul, C, Gattermann, N, Schneider, W. Age-related incidence and other epidemiological aspects of myelodysplastic syndromes. Br J Haematol. 1992;82(2):358–367.CrossRefGoogle ScholarPubMed

Quesnel, B, Guillerm, G, Vereecque, R. Methylation of the p15(INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood. 1998;91(8):2985–2990.Google ScholarPubMed

Bottomley, A, Vanvoorden, V, Flechtner, H. EORTC Quality of Life Group EORTC Data Center. The challenges and achievements involved in implementing quality of life research in cancer clinical trials. Eur J Cancer. 2003;39(3):275–285.CrossRefGoogle ScholarPubMed

Boogaerts, M, Coiffier, B, Kainz, C. Epoetin beta QOL Working Group. Impact of epoetin beta on quality of life in patients with malignant disease. Br J Cancer. 2003;88(7):988–995.CrossRefGoogle Scholar

Wedding, U, Rohrig, B, Pientka, L. Anaemia-related impairment in quality of life in elderly cancer patients prior to chemotherapy. J Cancer Res Clin Oncol. 2007;133(5):279–286.CrossRefGoogle Scholar

Mancuso, A, Migliorino, M, Santis, S. Correlation between anemia and functional/cognitive capacity in elderly lung cancer patients treated with chemotherapy. Ann Oncol. 2006;17(1):146–150.CrossRefGoogle ScholarPubMed

Penninx, BW, Pluijm, SM, Lips, P. Late-life anemia is associated with increased risk of recurrent falls. J Am Geriatr Soc. 2005;53(12):2106–2111.CrossRefGoogle ScholarPubMed

Penninx, BW, Guralnik, JM, Onder, G. Anemia and decline in physical performance among older persons. Am J Med. 2003;115(2):104–110.CrossRefGoogle ScholarPubMed

Chaves, PH, Ashar, B, Guralnik, JM. Looking at the relationship between hemoglobin concentration and prevalent mobility difficulty in older women: should the criteria currently used to define anemia in older people be reevaluated? J Am Geriatr Soc. 2002;50(7):1257–1264.CrossRefGoogle ScholarPubMed

Wu, WC, Rathore, SS, Wang, Y. Blood transfusion in elderly patients with acute myocardial infarction. N Engl J Med. 2001;345(17):1230–1236.CrossRefGoogle ScholarPubMed

Beard, CM, Kokmen, E, O';Brien, PC. Risk of Alzheimer's disease among elderly patients with anemia: population-based investigations in Olmsted County, Minnesota. Ann Epidemiol. 1997;7(3):219–224.CrossRefGoogle ScholarPubMed

Pinquart, M, Duberstein, PR. Information needs and decision-making processes in older cancer patients. Crit Rev Oncol Hematol. 2004;51(1):69–80.CrossRefGoogle ScholarPubMed

Rai, KR, Sawitsky, A, Cronkite, EP. Clinical staging of chronic lymphocytic leukemia. Blood. 1975;46(2):219–234.Google ScholarPubMed

Binet, JL, Auquier, A, Dighiero, G. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer. 1981;48(1):198–206.3.0.CO;2-V>CrossRefGoogle ScholarPubMed

Durie, BG, Salmon, SE. A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36(3):842–854.3.0.CO;2-U>CrossRefGoogle Scholar

Gobbi, PG, Zinzani, PL, Broglia, C. Comparison of prognostic models in patients with advanced Hodgkin disease: promising results from integration of the best three systems. Cancer. 2001;91(8):1467–1478.3.0.CO;2-A>CrossRefGoogle ScholarPubMed

Moullet, I, Salles, G, Ketterer, N. Frequency and significance of anemia in non-Hodgkin's lymphoma patients. Ann Oncol. 1998;9(10):1109–1115.CrossRefGoogle ScholarPubMed

Wigren, T, Oksanen, H, Kellokumpu-Lehtinen, P. A practical prognostic index for inoperable non-small-cell lung cancer. J Cancer Res Clin Oncol. 1997;123(5):259–266.CrossRefGoogle ScholarPubMed

Lee, WR, Berkey, B, Marcial, V. Anemia is associated with decreased survival and increased locoregional failure in patients with locally advanced head and neck carcinoma: a secondary analysis of RTOG 85–27. Int J Radiat Oncol Biol Phys. 1998;42(5):1069–1075.CrossRefGoogle ScholarPubMed

Berry, WR, Laszlo, J, Cox, E. Prognostic factors in metastatic and hormonally unresponsive carcinoma of the prostate. Cancer. 1979;44(2):763–775.3.0.CO;2-5>CrossRefGoogle ScholarPubMed

Gospodarowicz, MK, Hawkins, NV, Rawlings, GA. Radical radiotherapy for muscle invasive transitional cell carcinoma of the bladder: failure analysis. J Urol. 1989;142(6):1448–1453; discussion 1453–1454.CrossRefGoogle ScholarPubMed

Citterio, G, Bertuzzi, A, Tresoldi, M. Prognostic factors for survival in metastatic renal cell carcinoma: retrospective analysis from 109 consecutive patients. Eur Urol. 1997;31(3):286–291.CrossRefGoogle ScholarPubMed

Obermair, A, Handisurya, A, Kaider, A. The relationship of pretreatment serum hemoglobin level to the survival of epithelial ovarian carcinoma patients: a prospective review. Cancer. 1998;83(4):726–731.3.0.CO;2-U>CrossRefGoogle ScholarPubMed

Pedersen, D, Sogaard, H, Overgaard, J. Prognostic value of pretreatment factors in patients with locally advanced carcinoma of the uterine cervix treated by radiotherapy alone. Acta Oncol. 1995;34(6):787–795.CrossRefGoogle ScholarPubMed

Caro, JJ, Salas, M, Ward, A. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer. 2001;91(12):2214–2221.3.0.CO;2-P>CrossRefGoogle ScholarPubMed

Harrison, LB, Shasha, D, Homel, P. Prevalence of anemia in cancer patients undergoing radiotherapy: prognostic significance and treatment. Oncology. 2002;63(suppl 2):11–18.CrossRefGoogle ScholarPubMed

Lacombe, C, Da Silva, JL, Bruneval, P. Peritubular cells are the site of erythropoietin synthesis in the murine hypoxic kidney. J Clin Invest. 1988;81(2):620–623.CrossRefGoogle ScholarPubMed

Krantz, SB. Erythropoietin. Blood. 1991;77(3):419–434.Google ScholarPubMed

Jacobs, K, Shoemaker, C, Rudersdorf, R. Isolation and characterization of genomic and cDNA clones of human erythropoietin. Nature. 1985;313(6005):806–810.CrossRefGoogle ScholarPubMed

Lin, FK, Suggs, S, Lin, CH. Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci U S A. 1985;82(22):7580–7584.CrossRefGoogle ScholarPubMed

Storring, PL, Tiplady, RJ, Gaines Das, RE. Epoetin alfa and beta differ in their erythropoietin isoform compositions and biological properties. Br J Haematol. 1998;100(1):79–89.Google ScholarPubMed

Macdougall, IC, Gray, SJ, Elston, O. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol. 1999;10(11):2392–2395.Google ScholarPubMed

Rizzo, JD, Somerfield, MR, Hagerty, KL. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update. Blood. 2008;111(1):25–41.CrossRefGoogle ScholarPubMed

Vansteenkiste, J, Pirker, R, Massuti, B. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst. 2002;94(16):1211–1220.CrossRefGoogle ScholarPubMed

Schwartzberg, LS, Yee, LK, Senecal, FM. A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer. Oncologist. 2004;9(6):696–707.CrossRefGoogle ScholarPubMed

Kotasek, D, Steger, G, Faught, W. Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study. Eur J Cancer. 2003;39(14):2026–2034.CrossRefGoogle ScholarPubMed

Bennett, CL, Luminari, S, Nissenson, AR. Pure red-cell aplasia and epoetin therapy. N Engl J Med. 2004;351(14):1403–1408.CrossRefGoogle ScholarPubMed

Ben-Hamadi, R, Duh, MS, Aggarwal, J. The cost-effectiveness of weekly epoetin alfa relative to weekly darbepoetin alfa in patients with chemotherapy-induced anemia. Curr Med Res Opin. 2005;21(10):1677–1682.CrossRefGoogle ScholarPubMed

Seidenfeld, J, Piper, M, Flamm, C. Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials. J Natl Cancer Inst. 2001;93(16):1204–1214.CrossRefGoogle ScholarPubMed

Yellen, SB, Cella, DF, Webster, K. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage. 1997;13(2):63–74.CrossRefGoogle ScholarPubMed

Bohlius, J, Wilson, J, Seidenfeld, J. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst. 2006;98(10):708–714.CrossRefGoogle ScholarPubMed

Aapro, MS, Dale, DC, Blasi, M. Epoetin alfa increases hemoglobin levels and improves quality of life in anemic geriatric cancer patients receiving chemotherapy. Support Care Cancer. 2006;14(12):1184–1194.CrossRefGoogle ScholarPubMed

Boccia, R, Lillie, T, Tomita, D. The effectiveness of darbepoetin alfa administered every 3 weeks on hematologic outcomes and quality of life in older patients with chemotherapy-induced anemia. Oncologist. 2007;12(5):584–593.CrossRefGoogle ScholarPubMed

Cascinu, S, Del Ferro, E, Fedeli, A. Recombinant human erythropoietin treatment in elderly cancer patients with cisplatin-associated anemia. Oncology. 1995;52(5):422–426.CrossRefGoogle ScholarPubMed

Agnihotri, P, Telfer, M, Butt, Z. Chronic anemia and fatigue in elderly patients: results of a randomized, double-blind, placebo-controlled, crossover exploratory study with epoetin alfa. J Am Geriatr Soc. 2007;55(10):1557–1565.CrossRefGoogle ScholarPubMed

Ershler, WB, Artz, AS, Kandahari, MM. Recombinant erythropoietin treatment of anemia in older adults. J Am Geriatr Soc. 2001;49(10):1396–1397.CrossRefGoogle ScholarPubMed

Moreno, F, Aracil, FJ, Perez, R. Controlled study on the improvement of quality of life in elderly hemodialysis patients after correcting end-stage renal disease-related anemia with erythropoietin. Am J Kidney Dis. 1996;27(4):548–556.CrossRefGoogle ScholarPubMed

Besarab, A, Bolton, WK, Browne, JK. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339(9):584–590.CrossRefGoogle ScholarPubMed

Singh, AK, Szczech, L, Tang, KL. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355(20):2085–2098.CrossRefGoogle ScholarPubMed

Drueke, TB, Locatelli, F, Clyne, N. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355(20):2071–2084.CrossRefGoogle ScholarPubMed

Henke, M, Laszig, R, Rube, C. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet. 2003;362(9392):1255–1260.CrossRefGoogle ScholarPubMed

Leyland-Jones, B, Semiglazov, V, Pawlicki, M. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol. 2005;23(25):5960–5972.CrossRefGoogle ScholarPubMed

Overgaard, J, Hoff, C, Sand, HH. Randomized study of the importance of novel erythropoiesis stimulating protein (Aranesp) for the effect of radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC) – the Danish Head and Neck Cancer Group DAHANCA 10 randomized trial. Eur J Cancer. 2007;5(suppl):7.Google Scholar

Thomas, G, Ali, S, Hoebers, FJ. Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer. Gynecol Oncol. 2008;108(2):317–325.CrossRefGoogle Scholar

Wright, JR, Ung, YC, Julian, JA. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol. 2007;25(9):1027–1032.CrossRefGoogle ScholarPubMed

Smith Jr, RE, Aapro, MS, Ludwig, H. Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. J Clin Oncol. 2008;26(7):1040–1050.CrossRefGoogle Scholar

Bennett, CL, Silver, SM, Djulbegovic, B. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. J Am Med Assoc. 2008;299(8):914–924.CrossRefGoogle ScholarPubMed

Wilson, J, Yao, GL, Raftery, J. A systematic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment. Health Technol Assess. 2007;11(13):1–202.CrossRefGoogle ScholarPubMed

Rizzo, JD, Somerfield, MR, Hagerty, KL. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J Clin Oncol. 2008;26(1):132–149.CrossRefGoogle Scholar

Szczech, , Barnhart, HX, Inrig, JK. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int. 2008;74(6):791–798.CrossRefGoogle ScholarPubMed

Broudy, VC, Lin, N, Brice, M. Erythropoietin receptor characteristics on primary human erythroid cells. Blood. 1991;77(12):2583–2590.Google ScholarPubMed

Fraser, JK, Tan, AS, Lin, FK. Expression of specific high-affinity binding sites for erythropoietin on rat and mouse megakaryocytes. Exp Hematol. 1989;17(1):10–16.Google ScholarPubMed

Anagnostou, A, Liu, Z, Steiner, M. Erythropoietin receptor mRNA expression in human endothelial cells. Proc Natl Acad Sci U S A. 1994;91(9):3974–3978.CrossRefGoogle ScholarPubMed

Masuda, S, Nagao, M, Takahata, K. Functional erythropoietin receptor of the cells with neural characteristics: comparison with receptor properties of erythroid cells. J Biol Chem. 1993;268(15):11208–11216.Google ScholarPubMed

Witthuhn, BA, Quelle, FW, Silvennoinen, O. JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin. Cell. 1993;74(2):227–236.CrossRefGoogle ScholarPubMed

Mayeux, P, Dusanter-Fourt, I, Muller, O. Erythropoietin induces the association of phosphatidylinositol 3′-kinase with a tyrosine-phosphorylated protein complex containing the erythropoietin receptor. Eur J Biochem. 1993;216(3):821–828.CrossRefGoogle ScholarPubMed

Gobert, S, Duprez, V, Lacombe, C. The signal transduction pathway of erythropoietin involves three forms of mitogen-activated protein (MAP) kinase in UT7 erythroleukemia cells. Eur J Biochem. 1995;234(1):75–83.CrossRefGoogle ScholarPubMed

Gouilleux, F, Pallard, C, Dusanter-Fourt, I. Prolactin, growth hormone, erythropoietin and granulocyte-macrophage colony stimulating factor induce MGF-Stat5 DNA binding activity. EMBO J. 1995;14(9):2005–2013.Google ScholarPubMed

Pallard, C, Gouilleux, F, Charon, M. Interleukin-3, erythropoietin, and prolactin activate a STAT5-like factor in lymphoid cells. J Biol Chem. 1995;270(27):15942–15945.CrossRefGoogle ScholarPubMed

Acs, G, Acs, P, Beckwith, SM. Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res. 2001;61(9):3561–3565.Google ScholarPubMed

Arcasoy, MO, Amin, K, Karayal, AF. Functional significance of erythropoietin receptor expression in breast cancer. Lab Invest. 2002;82(7):911–918.CrossRefGoogle ScholarPubMed

Elliott, S, Busse, L, Bass, MB. Anti-Epo receptor antibodies do not predict Epo receptor expression. Blood. 2006;107(5):1892–1895.CrossRefGoogle Scholar

Acs, G, Zhang, PJ, Rebbeck, TR. Immunohistochemical expression of erythropoietin and erythropoietin receptor in breast carcinoma. Cancer. 2002;95(5):969–981.CrossRefGoogle ScholarPubMed

Brown, WM, Maxwell, P, Graham, AN. Erythropoietin receptor expression in non-small cell lung carcinoma: a question of antibody specificity. Stem Cells. 2007;25(3):718–722.CrossRefGoogle ScholarPubMed

LaMontagne, KR, Butler, J, Marshall, DJ. Recombinant epoetins do not stimulate tumor growth in erythropoietin receptor-positive breast carcinoma models. Mol Cancer Ther. 2006;5(2):347–355.CrossRefGoogle Scholar

Mohyeldin, A, Dalgard, CL, Lu, H. Survival and invasiveness of astrocytomas promoted by erythropoietin. J Neurosurg. 2007;106(2):338–350.CrossRefGoogle ScholarPubMed

Gewirtz, DA, Di, X, Walker, TD. Erythropoietin fails to interfere with the antiproliferative and cytotoxic effects of antitumor drugs. Clin Cancer Res. 2006;12(7 Pt 1):2232–2238.CrossRefGoogle ScholarPubMed

Westenfelder, C, Baranowski, RL. Erythropoietin stimulates proliferation of human renal carcinoma cells. Kidney Int. 2000;58(2):647–657.CrossRefGoogle ScholarPubMed

Liu, WM, Powles, T, Shamash, J. Effect of haemopoietic growth factors on cancer cell lines and their role in chemosensitivity. Oncogene. 2004;23(4):981–990.CrossRefGoogle ScholarPubMed

Hale, SA, Wong, C, Lounsbury, KM. Erythropoietin disrupts hypoxia-inducible factor signaling in ovarian cancer cells. Gynecol Oncol. 2006;100(1):14–19.CrossRefGoogle ScholarPubMed

Taylor, JE, Henderson, IS, Stewart, WK. Erythropoietin and spontaneous platelet aggregation in haemodialysis patients. Lancet. 1991;338(8779):1361–1362.CrossRefGoogle ScholarPubMed

Macdougall, IC, Davies, ME, Hallett, I. Coagulation studies and fistula blood flow during erythropoietin therapy in haemodialysis patients. Nephrol Dial Transplant. 1991;6(11):862–867.CrossRefGoogle ScholarPubMed

Diskin, CJ, Stokes, Jr TJ, Pennell, AT. Pharmacologic intervention to prevent hemodialysis vascular access thrombosis. Nephron. 1993;64(1):1–26.CrossRefGoogle ScholarPubMed

Moyo, V, Lefebvre, P, Duh, MS. Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analysis. Ann Hematol. 2008;87(7):527–536.CrossRefGoogle ScholarPubMed

Jadersten, M, Malcovati, L, Dybedal, I. Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. J Clin Oncol. 2008;26(21):3607–3613.CrossRefGoogle ScholarPubMed

Greenberg, PL, Attar, E, Battiwalla, M. NCCN Guidelines in Clinical Oncology: myelodysplastic syndromes. National Comprehensive Cancer Network Web site. Available at: http://www.nccn.org/professionals/physician_gls/PDF/mds.pdf.

Grote, T, Yeilding, AL, Castillo, R. Efficacy and safety analysis of epoetin alfa in patients with small-cell lung cancer: a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2005;23(36):9377–9386.CrossRefGoogle ScholarPubMed